Difference between revisions of "Apraclonidine"
m (Citations: [Pu184]Tweaked: journal, doi. You can use this bot yourself. Report bugs here.) |
m (1 revision) |
(No difference)
|
Latest revision as of 10:20, 20 September 2010
File:Apraclonidine structure.svg | |
Systematic (IUPAC) name | |
---|---|
2,6-dichloro-N- (4,5-dihydro-1H-imidazol-2-yl) benzene-1,4-diamine | |
Clinical data | |
Routes of administration | Ophthalmic solution |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 98.7% |
Biological half-life | 8 hours |
Identifiers | |
CAS Number | 66711-21-5 |
ATC code | S01EA03 (WHO) |
PubChem | CID 2216 |
DrugBank | APRD00012 |
ChemSpider | 2130 |
Chemical data | |
Formula | C9H10Cl2N4 |
Molar mass | 245.108 g/mol[[Script error: No such module "String".]] |
Script error: No such module "collapsible list". | |
(verify) |
Apraclonidine (INN), also known as Iopidine, is a sympathomimetic used in glaucoma therapy. It is an α2-adrenergic agonist.
Apraclonidine is administered at a concentration of 1% for the prevention and treatment of postsurgical intraocular pressure elevation and 0.5% for short-term adjunctive therapy in patients on maximally tolerated medical therapy who require additional redirection of intraocular pressure. One drop is usually added one hour prior to laser eye surgery and another drop is given after the procedure is complete.
Clinical uses
Apraclonidine is indicated for the short-term adjunctive treatment of patients on maximally tolerated medical therapy who require additional IOP reduction. Patients on maximally tolerated medical therapy who are treated with apraclonidine to delay surgery should have frequent followup examinations and treatment should be discontinued if the intraocular pressure rises significantly.
External links
- Iopidine prescribing information (from the FDA website)
- Simple information on Apraclonidine
References
- Chen P, Chen J, Lu D, Chen Y, Hsiao C (2006). "Comparing efficacies of 0.5% apraclonidine with 4% cocaine in the diagnosis of horner syndrome in pediatric patients". J Ocul Pharmacol Ther. 22 (3): 182–7. doi:10.1089/jop.2006.22.182. PMID 16808679.
- Aslanides l, Tsiklis N, Ozkilic E, Coskunseven E, Pallikaris l, Jankov M (2006). "The effect of topical apraclonidine on subconjunctival hemorrhage and flap adherence in LASIK patients". J Refract Surg. 22 (6): 585–8. PMID 16805122.
- Koc F, Kansu T, Kavuncu S, Firat E (2006). "Topical apraclonidine testing discloses pupillary sympathetic denervation in diabetic patients". J Neuroophthalmol. 26 (1): 25–9. doi:10.1097/01.wno.0000204648.79744.71. PMID 16518162.
- Garibaldi D, Hindman H, Grant M, Iliff N, Merbs S (2006). "Effect of 0.5% apraclonidine on ptosis in Horner syndrome". Ophthal Plast Reconstr Surg. 22 (1): 53–5. doi:10.1097/01.iop.0000196322.05586.6a. PMID 16418668.
- Onal S, Gozum N, Gucukoglu A (2005). "Effect of apraclonidine versus dorzolamide on intraocular pressure after phacoemulsification". Ophthalmic Surg Lasers Imaging. 36 (6): 457–62. PMID 16355950.
- Pages with script errors
- Pages with broken file links
- Drugs with non-standard legal status
- Infobox drug tracked parameters
- Articles without EBI source
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- CS1 maint: Multiple names: authors list
- Alpha-adrenergic agonists
- Sympathomimetic amines
- Guanidines
- Imidazolines
- Organochlorides
- 2Fix